Pregnancy registry
ADEPT: feasibility of estimating the risk of adverse pregnancy, neonatal and child outcomes following either in utero ASM exposure through the mother, or peri-conceptional ASM exposure through the father
Finland
France
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000246
First published:
31/03/2026
Study
Ongoing
A Post-Marketing Safety Study using a Pregnancy Registry to Evaluate the Safety of Respiratory Syncytial Virus Vaccine (ABRYSVO™) Exposure During Pregnancy (C3671041)
United States
EU PAS number:
EUPAS1000000179
First published:
26/01/2026
Study
Ongoing
Antipsychotics in pregnancy and the risk of adverse pregnancy outcomes - a nationwide study
Norway
EU PAS number:
EUPAS1000000134
First published:
28/02/2025
Study
Planned
QUVIVIQ® Pregnancy Registry (ID-078A403)
Canada
France
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS1000000033
First published:
18/12/2025
Study
Ongoing
MS700568_0004: Pregnancy outcomes in women exposed to oral cladribine: a multi-country cohort database study (CLEAR)
Denmark
Finland
France
Germany
Norway
Sweden
United Kingdom
EU PAS number:
EUPAS25027
First published:
25/03/2026
Study
Ongoing
Vedolizumab-5001: Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry
Canada
United States
EU PAS number:
EUPAS11681
First published:
21/11/2024
Study
Finalised
Strengthening Use of Real-World Data in Medicines Development: Metadata for Data Discoverability and Study Replicability (MINERVA)
Austria
Belgium
Czechia
Denmark
Estonia
France
Germany
Italy
Netherlands
Slovenia
Spain
Sweden
Switzerland
United Kingdom
EU PAS number:
EUPAS39322
First published:
16/12/2024
Study
Finalised
The Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis (Gilenya Pregnancy Registry)
Argentina
Australia
Austria
Canada
Cyprus
Czechia
Denmark
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Lebanon
Mexico
Netherlands
Poland
Portugal
Russian Federation
Saudi Arabia
Spain
Sweden
Switzerland
United Arab Emirates
United Kingdom
United States
EU PAS number:
EUPAS2569
First published:
04/06/2025
Study
Finalised
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
United States
EU PAS number:
EUPAS45356
First published:
26/03/2026
Study
Ongoing
Postmarketing safety study based on Pregnancy Registry on women exposed to Palforzia during pregnancy and on infants exposed to Palforzia in utero
Austria
France
Germany
Switzerland
United Kingdom
United States
EU PAS number:
EUPAS41546
First published:
13/02/2026
Study
Finalised